Abstract
Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated the efficacy and toxicity of reduced-dose (two-thirds) R-CHOP chemotherapy as an initial chemotherapy for 45 patients aged 70 years or older with B-cell NHL. The WHO classification of NHL included diffuse large B-cell lymphoma (DLBCL) (31), mantle cell lymphoma (5), follicular lymphoma (4), extranodal marginal zone lymphoma (1), Burkitt lymphoma (1), and B-cell lymphoma whose further types were unclassified (3). The incidences of grade 4 neutropenia and febrile neutropenia (FN) were 51.1 and 15.6%, respectively. Efficacy was evaluated in patients with DLBCL. The overall and complete response (CR) rates were 96.7 and 90.0%, respectively. Two-year event-free survival (EFS) and overall survival (OS) were 84.4 and 89.2%, respectively. There was no treatment-related mortality. In conclusion, two-thirds R-CHOP chemotherapy is a promising treatment for elderly patients with B-cell NHL in terms of its efficacy and toxicity.
Keywords:
Diffuse large B-cell lymphoma,; Elderly patients,; Neutropenia,; Non-Hodgkin lymphoma,; R-CHOP; Relative dose intensity,; Rituximab,.
MeSH terms
-
Academic Medical Centers
-
Aged
-
Aged, 80 and over
-
Aging*
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived / adverse effects
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Chemotherapy-Induced Febrile Neutropenia / epidemiology
-
Chemotherapy-Induced Febrile Neutropenia / physiopathology
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Female
-
Follow-Up Studies
-
Humans
-
Incidence
-
Japan / epidemiology
-
Lymphoma, Non-Hodgkin / diagnosis
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Male
-
Neoplasm Staging
-
Neutropenia / chemically induced
-
Neutropenia / epidemiology
-
Neutropenia / physiopathology
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Prognosis
-
Retrospective Studies
-
Risk
-
Rituximab
-
Severity of Illness Index
-
Survival Analysis
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
R-CHOP protocol
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone